VIVUS, Inc. (NASDAQ:VVUS)
A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
manirg
(39.06)
Submitted: 6/14/2013 12:48:32 PM :
Start Price:
$14.24
VVUS Score:
-4.60
obesity drug will catch on
Recs
Mernest
(54.01)
Submitted: 5/7/2013 9:09:13 AM :
Start Price:
$12.24
VVUS Score:
+10.19
Correction as of 2 monthes ago ready for increase.
Recs
VictorLeung
(< 20)
Submitted: 4/26/2013 1:16:09 PM :
Start Price:
$12.84
VVUS Score:
+2.29
It seems that their Stendra(ED Drug) is better than Viagra. Stendra is going to market.
Recs
LIFESAVA1
(< 20)
Submitted: 4/19/2013 5:31:47 PM :
Start Price:
$11.88
VVUS Score:
+9.43
VVUS HAS A GREAT WEIGHT LOSS PRODUCT
Recs
TheStockDoctor
(53.64)
Submitted: 3/3/2013 9:37:23 PM :
Start Price:
$10.24
VVUS Score:
-25.17
Qsymia was a total flop at initial release, and that is without any competition. As soon as Belviq hits the shelves, Qsymia sales will drop substantially.
Recs
gatzbp
(82.81)
Submitted: 2/22/2013 11:26:19 AM :
Start Price:
$12.28
VVUS Score:
+2.35
even without Europe, the drug has massive sales potential.
Recs
SmartEquity
(< 20)
Submitted: 1/21/2013 9:09:52 AM :
Start Price:
$13.34
VVUS Score:
-8.59
I believe the scrips will pick up as distribution is improved. The obesity patients will choose a riskier Qsymia over a safer less effective Belviq.
Recs
clymerjones
(54.39)
Submitted: 10/17/2012 11:09:13 AM :
Start Price:
$22.25
VVUS Score:
-51.65
Strong product/development initiatives will out class the S&P
Recs
greatspeculator
(61.16)
Submitted: 10/3/2012 2:00:40 AM :
Start Price:
$18.51
VVUS Score:
-40.05
Good fundamentals. Speculation.
Recs
dausama
(72.89)
Submitted: 9/23/2012 9:54:13 AM :
Start Price:
$20.62
VVUS Score:
+47.45
no EU approval
Recs
PokesCAPS
(< 20)
Submitted: 8/13/2012 8:48:02 AM :
Start Price:
$21.61
VVUS Score:
-54.20
potential to fly, but very risky
Recs
donodonuts
(50.66)
Submitted: 8/9/2012 7:16:43 AM :
Start Price:
$21.77
VVUS Score:
-54.93
Sold it at like 8, oops. But their stuff hasn't hit the market yet, I'd like to think it will go up more when they have actual sales.
Recs
rick3000
(< 20)
Submitted: 7/17/2012 5:16:39 PM :
Start Price:
$30.33
VVUS Score:
+76.46
Inflated by ARNA approval, will crash to actual value if rejected or with restrictive label. Management has a black eye from handling of FDA announcement.
Recs
ravens9111
(61.64)
Submitted: 7/16/2012 11:26:58 AM :
Start Price:
$27.97
VVUS Score:
+72.99
Betting against this stock's FDA decision tomorrow. Price is most likely already priced in for approval. I expect a sell the news event even if approval is granted. However, if rejected, this stock will go to low teens to high single digits.
Recs
HIGHG33K
(65.56)
Submitted: 7/13/2012 8:39:49 PM :
Start Price:
$27.55
VVUS Score:
-72.42
FDA approval is inevitable.
Recs
natemwilson
(33.47)
Submitted: 6/28/2012 12:08:47 PM :
Start Price:
$28.54
VVUS Score:
+77.46
Too many adverse side effects to be approved.
Recs
nobleartjim
(< 20)
Submitted: 6/23/2012 9:48:19 AM :
Start Price:
$26.34
VVUS Score:
-73.27
Recent developing products now undergoing FDA tests appear favorable
Recs
BACnumber1
(< 20)
Submitted: 6/12/2012 12:13:40 PM :
Start Price:
$24.75
VVUS Score:
-69.82
Fine stock, but I'm way bigger on ARNA
Recs
GoodTrader1
(< 20)
Submitted: 6/6/2012 4:38:42 PM :
Start Price:
$24.32
VVUS Score:
-67.60
high relative strenght
Recs
Wanker01
(< 20)
Submitted: 5/1/2012 1:07:03 PM :
Start Price:
$24.59
VVUS Score:
-61.19
Old people want to do it to
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 91 : 1 2 3 4 5 Next »